Hagit Eldar-Finkelman


Affiliation: Tel Aviv University
Country: Israel


  1. request reprint
    Eldar Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med. 2002;8:126-32 pubmed
    ..Finally, selective inhibitors of GSK-3 could mimic the action of mood stabilizers such as lithium and valproic acid and be used in the treatment of bipolar mood disorders. ..
  2. request reprint
    Eldar Finkelman H, Eisenstein M. Peptide inhibitors targeting protein kinases. Curr Pharm Des. 2009;15:2463-70 pubmed
    ..In this review we focus on the strategies to design such peptide inhibitors, focusing mainly on the serine/threonine protein kinase family. ..
  3. request reprint
    Licht Murava A, Paz R, Vaks L, Avrahami L, Plotkin B, Eisenstein M, et al. A unique type of GSK-3 inhibitor brings new opportunities to the clinic. Sci Signal. 2016;9:ra110 pubmed
    ..This new modality of GSK-3 inhibition may be therapeutic in patients with AD or other central nervous system disorders associated with dysregulated GSK-3. ..